Evan Seigerman
Stock Analyst at BMO Capital
(4.00)
# 580
Out of 5,090 analysts
150
Total ratings
55%
Success rate
10.39%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $1,010.31 | +18.78% | 10 | Dec 4, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $22 → $30 | $29.36 | +2.18% | 2 | Nov 18, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $455.48 | +16.36% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $102.52 | -41.47% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $93.29 | +28.63% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $155.51 | -26.05% | 15 | May 6, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $115 → $120 | $121.22 | -1.01% | 17 | Apr 17, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $181.30 | -23.33% | 27 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $52.15 | +16.97% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $34.56 | +15.74% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $10.61 | +277.00% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $718.36 | +9.69% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $8.55 | -70.76% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $329.89 | -26.34% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.33 | +125.14% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $26.03 | +130.50% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.37 | +2,089.78% | 3 | May 12, 2020 |
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $1,010.31
Upside: +18.78%
Terns Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $22 → $30
Current: $29.36
Upside: +2.18%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $455.48
Upside: +16.36%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $102.52
Upside: -41.47%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $93.29
Upside: +28.63%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $155.51
Upside: -26.05%
Gilead Sciences
Apr 17, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $121.22
Upside: -1.01%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $181.30
Upside: -23.33%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $52.15
Upside: +16.97%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $34.56
Upside: +15.74%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $10.61
Upside: +277.00%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $718.36
Upside: +9.69%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $8.55
Upside: -70.76%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $329.89
Upside: -26.34%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.33
Upside: +125.14%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $26.03
Upside: +130.50%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.37
Upside: +2,089.78%